Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Calvez

Showing results (141-150 of 329) with videos related to

Pageof 33
Sort By:
AIDS (London, England)|December 6, 2005
Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patientsSamir Vora, Anne-Geneviève Marcelin, Huldrych F Günthard, et al.
Journal of Medical Virology|December 21, 2006
Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS studyStephanie Dominguez, Jade Ghosn, Gilles Peytavin, et al.
AIDS (London, England)|June 3, 2009
Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trialCathia Soulié, Lambert Assoumou, Jade Ghosn, et al.
The Journal of Antimicrobial Chemotherapy|April 30, 2015
Low-level HIV-1 viraemia in patients on HAART: risk factors and management in clinical practiceMarc Wirden, Eve Todesco, Marc-Antoine Valantin, et al.
AIDS (London, England)|August 2, 2003
Clinically relevant interpretation of genotype for resistance to abacavirFrançoise Brun-Vézinet, Diane Descamps, Annick Ruffault, et al.
Journal of Clinical Microbiology|June 7, 2003
Interruption of nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy for 2 months has no effect on levels of human immunodeficiency virus type 1 in plasma of patients harboring viruses with mutations associated with resistance to NNRTIsMarc Wirden, Anne Simon, Luminita Schneider, et al.
AIDS (London, England)|April 13, 2004
Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097)Christine Katlama, Stéphanie Dominguez, Karine Gourlain, et al.
Antiviral Therapy|May 17, 2007
Genetic diversity and drug resistance mutations in HIV type 1 from untreated patients in Bamako, MaliAnne Derache, Ousmane Traore, Victoria Koita, et al.
Plos One|June 13, 2015
HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to MaravirocChristophe Rodriguez, Cathia Soulié, Anne-Geneviève Marcelin, et al.
Journal of Medical Virology|September 21, 2005
Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097)Constance Delaugerre, Gilles Peytavin, Stephanie Dominguez, et al.
Pageof 33

Showing results (141-150 of 329) with videos related to

Sort By:
Pageof 33
AIDS (London, England)|December 6, 2005
Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patientsSamir Vora, Anne-Geneviève Marcelin, Huldrych F Günthard, et al.
Journal of Medical Virology|December 21, 2006
Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS studyStephanie Dominguez, Jade Ghosn, Gilles Peytavin, et al.
AIDS (London, England)|June 3, 2009
Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trialCathia Soulié, Lambert Assoumou, Jade Ghosn, et al.
The Journal of Antimicrobial Chemotherapy|April 30, 2015
Low-level HIV-1 viraemia in patients on HAART: risk factors and management in clinical practiceMarc Wirden, Eve Todesco, Marc-Antoine Valantin, et al.
AIDS (London, England)|August 2, 2003
Clinically relevant interpretation of genotype for resistance to abacavirFrançoise Brun-Vézinet, Diane Descamps, Annick Ruffault, et al.
Journal of Clinical Microbiology|June 7, 2003
Interruption of nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy for 2 months has no effect on levels of human immunodeficiency virus type 1 in plasma of patients harboring viruses with mutations associated with resistance to NNRTIsMarc Wirden, Anne Simon, Luminita Schneider, et al.
AIDS (London, England)|April 13, 2004
Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097)Christine Katlama, Stéphanie Dominguez, Karine Gourlain, et al.
Antiviral Therapy|May 17, 2007
Genetic diversity and drug resistance mutations in HIV type 1 from untreated patients in Bamako, MaliAnne Derache, Ousmane Traore, Victoria Koita, et al.
Plos One|June 13, 2015
HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to MaravirocChristophe Rodriguez, Cathia Soulié, Anne-Geneviève Marcelin, et al.
Journal of Medical Virology|September 21, 2005
Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097)Constance Delaugerre, Gilles Peytavin, Stephanie Dominguez, et al.
Pageof 33